A phase II study of (2″ R)-4′ -0-tetrahydropyranyladriamycin (THP) in hematological malignancies

✍ Scribed by Kazumasa Yamada; Shigeru Shirakawa; Ryuzo Ohno; Hideo Yamada; Yutaka Hirota; Kanji Ohara; Kaoru Yamagata; Masahide Kobayashi; Masami Hirano; Yasushi Ikeda; Takashi Oguri; Yasuharu Mitomo; Harumitsu Mizuno; Satoshi Yoshikawa; Hiroshi Shiku; Kiyoji Kimura

• Publisher: Springer US
• Year: 1987
• Tongue: English
• Weight: 441 KB
• Volume: 5
• Category: Article
• ISSN: 0167-6997
• DOI: 10.1007/bf00175302

✦ Synopsis

A phase II study of new anthracycline, THP, was conducted in 46 patients with hematological malignancies in a cooperative study. THP was given intravenously either at a dose of 13-34 mg/m 2 for 3-5 consecutive days or 35-50 mg/m 2 at 3-4 week intervals.

Of 21 patients with acute leukemia, complete response (CR) was observed in 3 patients and partial response (PR) in 4. Of 22 patients with malignant lymphoma, CR was observed in 2 and PR in 6.

The predominant toxicity was myelosuppression. Leukopenia was noted in 73% of patients and thrombocytopenia in 14%. Anorexia, nausea and vomiting were observed in 49%, 26% and 23%, respectively. Alopecia and acute cardiac toxicities were mild and recovered quickly on discontinuation of THP.

Thus, THP was found to be effective for acute leukemia and malignant lymphoma.